The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Secondary Hyperparathyroidism Treatment Market Research Report 2025
Synopsis
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
The global Secondary Hyperparathyroidism Treatment market was valued at US$ 3143.6 million in 2023 and is anticipated to reach US$ 4471.4 million by 2030, witnessing a CAGR of 5.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Secondary Hyperparathyroidism Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Secondary Hyperparathyroidism Treatment.
Report Scope
The Secondary Hyperparathyroidism Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Secondary Hyperparathyroidism Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Secondary Hyperparathyroidism Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Takeda
Sanofi
Deltanoid Pharmaceuticals
Segment by Type
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Segment by Application
Hospital Pharmacies
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Secondary Hyperparathyroidism Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Secondary hyperparathyroidism refers to the excessive secretion of parathyroid hormone by the parathyroid glands in response to hypocalcemia and associated hyperplasia of the glands.
The global Secondary Hyperparathyroidism Treatment market was valued at US$ 3143.6 million in 2023 and is anticipated to reach US$ 4471.4 million by 2030, witnessing a CAGR of 5.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Secondary Hyperparathyroidism Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Secondary Hyperparathyroidism Treatment.
Report Scope
The Secondary Hyperparathyroidism Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Secondary Hyperparathyroidism Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Secondary Hyperparathyroidism Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Amgen
OPKO Health
AbbVie
Astellas Pharma
Roche
KAI Pharmaceuticals
Kyowa Hakko Kirin
Leo Pharma
Takeda
Sanofi
Deltanoid Pharmaceuticals
Segment by Type
Surgery
Drugs
Vitamin D
Calcimimetics
Phosphate Binders
Segment by Application
Hospital Pharmacies
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Secondary Hyperparathyroidism Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Secondary Hyperparathyroidism Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Surgery
1.2.3 Drugs
1.2.4 Vitamin D
1.2.5 Calcimimetics
1.2.6 Phosphate Binders
1.3 Market by Application
1.3.1 Global Secondary Hyperparathyroidism Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Secondary Hyperparathyroidism Treatment Market Perspective (2019-2030)
2.2 Secondary Hyperparathyroidism Treatment Growth Trends by Region
2.2.1 Global Secondary Hyperparathyroidism Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Secondary Hyperparathyroidism Treatment Historic Market Size by Region (2019-2024)
2.2.3 Secondary Hyperparathyroidism Treatment Forecasted Market Size by Region (2025-2030)
2.3 Secondary Hyperparathyroidism Treatment Market Dynamics
2.3.1 Secondary Hyperparathyroidism Treatment Industry Trends
2.3.2 Secondary Hyperparathyroidism Treatment Market Drivers
2.3.3 Secondary Hyperparathyroidism Treatment Market Challenges
2.3.4 Secondary Hyperparathyroidism Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue
3.1.1 Global Top Secondary Hyperparathyroidism Treatment Players by Revenue (2019-2024)
3.1.2 Global Secondary Hyperparathyroidism Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Secondary Hyperparathyroidism Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Secondary Hyperparathyroidism Treatment Revenue
3.4 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio
3.4.1 Global Secondary Hyperparathyroidism Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Secondary Hyperparathyroidism Treatment Revenue in 2023
3.5 Secondary Hyperparathyroidism Treatment Key Players Head office and Area Served
3.6 Key Players Secondary Hyperparathyroidism Treatment Product Solution and Service
3.7 Date of Enter into Secondary Hyperparathyroidism Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Secondary Hyperparathyroidism Treatment Breakdown Data by Type
4.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Type (2019-2024)
4.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Type (2025-2030)
5 Secondary Hyperparathyroidism Treatment Breakdown Data by Application
5.1 Global Secondary Hyperparathyroidism Treatment Historic Market Size by Application (2019-2024)
5.2 Global Secondary Hyperparathyroidism Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Secondary Hyperparathyroidism Treatment Market Size (2019-2030)
6.2 North America Secondary Hyperparathyroidism Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Secondary Hyperparathyroidism Treatment Market Size by Country (2019-2024)
6.4 North America Secondary Hyperparathyroidism Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Secondary Hyperparathyroidism Treatment Market Size (2019-2030)
7.2 Europe Secondary Hyperparathyroidism Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2019-2024)
7.4 Europe Secondary Hyperparathyroidism Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size (2019-2030)
8.2 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Secondary Hyperparathyroidism Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Secondary Hyperparathyroidism Treatment Market Size (2019-2030)
9.2 Latin America Secondary Hyperparathyroidism Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2019-2024)
9.4 Latin America Secondary Hyperparathyroidism Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size (2019-2030)
10.2 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Secondary Hyperparathyroidism Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amgen
11.1.1 Amgen Company Detail
11.1.2 Amgen Business Overview
11.1.3 Amgen Secondary Hyperparathyroidism Treatment Introduction
11.1.4 Amgen Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.1.5 Amgen Recent Development
11.2 OPKO Health
11.2.1 OPKO Health Company Detail
11.2.2 OPKO Health Business Overview
11.2.3 OPKO Health Secondary Hyperparathyroidism Treatment Introduction
11.2.4 OPKO Health Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.2.5 OPKO Health Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Secondary Hyperparathyroidism Treatment Introduction
11.3.4 AbbVie Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Astellas Pharma
11.4.1 Astellas Pharma Company Detail
11.4.2 Astellas Pharma Business Overview
11.4.3 Astellas Pharma Secondary Hyperparathyroidism Treatment Introduction
11.4.4 Astellas Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.4.5 Astellas Pharma Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Secondary Hyperparathyroidism Treatment Introduction
11.5.4 Roche Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.5.5 Roche Recent Development
11.6 KAI Pharmaceuticals
11.6.1 KAI Pharmaceuticals Company Detail
11.6.2 KAI Pharmaceuticals Business Overview
11.6.3 KAI Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
11.6.4 KAI Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.6.5 KAI Pharmaceuticals Recent Development
11.7 Kyowa Hakko Kirin
11.7.1 Kyowa Hakko Kirin Company Detail
11.7.2 Kyowa Hakko Kirin Business Overview
11.7.3 Kyowa Hakko Kirin Secondary Hyperparathyroidism Treatment Introduction
11.7.4 Kyowa Hakko Kirin Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.7.5 Kyowa Hakko Kirin Recent Development
11.8 Leo Pharma
11.8.1 Leo Pharma Company Detail
11.8.2 Leo Pharma Business Overview
11.8.3 Leo Pharma Secondary Hyperparathyroidism Treatment Introduction
11.8.4 Leo Pharma Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.8.5 Leo Pharma Recent Development
11.9 Takeda
11.9.1 Takeda Company Detail
11.9.2 Takeda Business Overview
11.9.3 Takeda Secondary Hyperparathyroidism Treatment Introduction
11.9.4 Takeda Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.9.5 Takeda Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Secondary Hyperparathyroidism Treatment Introduction
11.10.4 Sanofi Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.10.5 Sanofi Recent Development
11.11 Deltanoid Pharmaceuticals
11.11.1 Deltanoid Pharmaceuticals Company Detail
11.11.2 Deltanoid Pharmaceuticals Business Overview
11.11.3 Deltanoid Pharmaceuticals Secondary Hyperparathyroidism Treatment Introduction
11.11.4 Deltanoid Pharmaceuticals Revenue in Secondary Hyperparathyroidism Treatment Business (2019-2024)
11.11.5 Deltanoid Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
